Targets › GLS1
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2028.
Catalyzes the first reaction in the primary pathway for the renal catabolism of glutamine. Plays a role in maintaining acid-base homeostasis. (UniProt, O94925)
Open in Phaseline: the race on GLS1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| M.D. Anderson Cancer Center | IACS-6274 Glutaminase-1 inhibitor | GLS1 | Phase 1 | Advanced Endometrial Carcinoma | Mar 2028 |
Advanced Endometrial Carcinoma (1)
mixed (1)
M.D. Anderson Cancer Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.